Chen Mi, Xu Wangli, Ding Yan, Zhao Honglei, Wang Pei, Yang Bo, Qiao Huanyu, Zhang Wei, Zhou Chenyang, Jia Junnan, Bai Tao, Xue Jinrong, Zhu Junming, Liu Yongmin, Li Weimin, Sun Lizhong
Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Department of Cardiac Surgery, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Front Cardiovasc Med. 2021 Dec 22;8:771346. doi: 10.3389/fcvm.2021.771346. eCollection 2021.
We sought to evaluate the outcomes of integrated aortic-valve and ascending-aortic replacement (IR) vs. partial replacement (PR) in patients with bicuspid aortic valve (BAV)-related aortopathy. We compared long-term mortality, reoperation incidence, and the cumulative incidence of stroke, bleeding, significant native valve or prosthetic valve dysfunction, and the New York Heart Association (NYHA) functional classes II-IV between inverse probability-weighted cohorts of patients who underwent IR or PR for BAV-related aortopathy in a single center from 2002 to 2019. Patients were stratified into different aortic diameter groups ("valve type" vs. "aorta type"). Among patients with "valve type," aortic valve replacement in patients with an aortic diameter > 40 mm was associated with significantly higher 10-year mortality than IR compared with diameter 35-40 mm [17.49 vs. 5.28% at 10 years; hazard ratio (HR), 3.22; 95% CI, 1.52 to 6.85; = 0.002]. Among patients with "aorta type," ascending aortic replacement in patients with an aortic diameter 52-60 mm was associated with significantly higher 10-year mortality than IR compared with diameter 45-52 mm (14.49 vs. 1.85% at 10 years; HR, 0.04; 95% CI, 1.06 to 85.24; = 0.03). The long-term mortality and reoperation benefit that were associated with IR, as compared with PR, minimizing to 40 mm of the aortic diameter among patients with "valve type" and minimizing to 52 mm of the aortic diameter among patients with "aorta type." Treatment to Bicuspid Aortic Valve Related Aortopathy (BAVAo Registry): ChiCTR.org.cn no: ChiCTR2000039867.
我们试图评估在患有二叶式主动脉瓣(BAV)相关主动脉病变的患者中,主动脉瓣与升主动脉联合置换术(IR)对比部分置换术(PR)的疗效。我们比较了2002年至2019年在单一中心因BAV相关主动脉病变接受IR或PR的患者的逆概率加权队列之间的长期死亡率、再次手术发生率、中风、出血、严重的自体瓣膜或人工瓣膜功能障碍的累积发生率,以及纽约心脏协会(NYHA)心功能II-IV级情况。患者被分为不同的主动脉直径组(“瓣膜类型”与“主动脉类型”)。在“瓣膜类型”的患者中,与主动脉直径35 - 40 mm的患者相比,主动脉直径>40 mm的患者进行主动脉瓣置换时,其10年死亡率显著高于IR(10年时分别为17.49%和5.28%;风险比[HR],3.22;95%置信区间[CI],1.52至6.85;P = 0.002)。在“主动脉类型”的患者中,与主动脉直径45 - 52 mm的患者相比,主动脉直径52 - 60 mm的患者进行升主动脉置换时,其10年死亡率显著高于IR(10年时分别为14.49%和1.85%;HR,0.04;95% CI,1.06至85.24;P = 0.03)。与PR相比,IR在长期死亡率和再次手术方面的益处在于,将“瓣膜类型”患者的主动脉直径最小化至40 mm,将“主动脉类型”患者的主动脉直径最小化至52 mm。二叶式主动脉瓣相关主动脉病变治疗(BAVAo注册研究):中国临床试验注册中心编号:ChiCTR.org.cn编号:ChiCTR2000039867 。